Diffuse Large B-Cell Lymphoma — Trials

Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 355
Recruiting: 190
Ph III recruiting: 16
Growth YoY: −11.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (177)

clinicaltrialsPublishedShowing 851–900 of 1,150 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01796470	Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies	terminated	Phase 2	66	Gilead SciencesINDUSTRY	1	Jun 2, 2020	clinicaltrials
NCT03436771	Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product	terminated	—	4	Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY	1	May 4, 2020	clinicaltrials